Background-Group B coxsackieviruses (CVBs) are the prototypical agents of acute myocarditis and chronic dilated cardiomyopathy, but an effective targeted therapy is still not available. Here, we analyze the therapeutic potential of a soluble (s) virus receptor molecule against CVB3 myocarditis using a gene therapy approach. Methods and Results-We generated an inducible adenoviral vector (AdG12) for strict drug-dependent delivery of sCAR-Fc, a fusion protein composed of the coxsackievirus-adenovirus receptor (CAR) extracellular domains and the carboxyl terminus of human IgG1-Fc. Decoy receptor expression was strictly doxycycline dependent, with no expression in the absence of an inducer. CVB3 infection of HeLa cells was efficiently blocked by supernatant from AdG12-transduced cells, but only in the presence of doxycycline. After liver-specific transfer, AdG12 (plus doxycycline) significantly improved cardiac contractility and diastolic relaxation compared with a control vector in CVB3-infected mice if sCAR-Fc was induced before infection (left ventricular pressure 59Ϯ3.8 versus 45.4Ϯ2.7 mm Hg, median 59 versus 45.8 mm Hg, PϽ0.01; dP/dt max 3645.1Ϯ443.6 versus 2057.9Ϯ490.2 mm Hg/s, median 3526.6 versus 2072 mm Hg/s, PϽ0.01; and dP/dt min Ϫ2125.5Ϯ330.5 versus Ϫ1310.2Ϯ330.3 mm Hg/s, median Ϫ2083.7 versus Ϫ1295.9 mm Hg/s, PϽ0.01) and improved contractility if induced concomitantly with infection (left ventricular pressure 76.4Ϯ19.2 versus 56.8Ϯ10.3 mm Hg, median 74.8 versus 54.4 mm Hg, PϽ0.05; dP/dt max 5214.2Ϯ1786.2 versus 3011.6Ϯ918.3 mm Hg/s, median 5182.1 versus 3106.6 mm Hg/s, PϽ0.05), respectively.
group of Picornaviridae, is one of the most commonly identified infectious agents associated with acute and chronic myocarditis 1 ; it can also mediate infectious pancreatitis and meningitis. Acute enteroviral myocarditis may not lead to initial mortality, but there is strong evidence to show that it often leads to the insidious development of dilated cardiomyopathy. 1 Currently, enteroviral myocarditis is treated nonspecifically by palliative care, because no effective antiviral therapy is available. CVB load, replication, and persistence are directly associated with cardiac injury and progression of the disease. 2, 3 A direct cytopathic effect of CVB in vitro and the induction of cardiac injury in immunodeficient mice in vivo support the significance of direct virus-mediated cardiac injury in disease pathogenesis. 4 Specific targeting of CVB in viral myocarditis, therefore, will not only abrogate virus-mediated direct cardiac damage but will diminish immune responsemediated damage by blocking viral spread to uninfected tissue.
Clinical Perspective on p 2366
The coxsackievirus-adenovirus receptor (CAR) mediates cellular attachment for adenovirus subtypes A and C through F and is essential to permit infection of all 6 serotypes of CVB. 5 CAR is a member of the immunoglobulin superfamily that consists of 2 extracellular immunoglobulin-like domains (D1 and D2), a transmembrane domain, and an intracellular tail of variable length. 6 The N-terminal D1 domain has been shown to bind both adenovirus fiber knob protein and the canyon structure of CVB capsids. 7, 8 Soluble decoy viral receptors have been found to efficiently inhibit infection by rhinoviruses, measles viruses, and adenoviruses. 9 -11 Soluble CAR (sCAR) proteins inhibit CVB infection of susceptible target cells in vitro and in vivo. 12, 13 The interaction of CVB3 with sCAR leads to formation of altered particles that are characterized by loss of VP4 from the virion shell and subsequent irreversible loss of infectivity. 14, 15 However, severe side effects, with increased cardiac inflammation and heart injury, have been observed after treatment of CVB3infected mice with CAR4/7, a native sCAR variant with an intact CVB3-binding D1 domain, half of the D2 domain, and a 23-amino acid-long C-terminus. 16 Previous investigations have shown that dimeric sCAR, expressed as an immunoglobulin Fc-region fusion protein, has reduced systemic clearance and increased virusneutralizing capacity relative to monomeric sCAR and does not induce undesirable side effects. 14 Therefore, the aim of the present study was to create an in vivo delivery system that would express sCAR-Fc in the liver for systemic release under the tight control of an inducible promoter. An adenoviral vector (AdV) was constructed that only expressed sCAR-Fc in the presence of doxycycline (Dox). It was our primary hypothesis that delivery of sCAR-Fc via a recombinant adenovirus expression vector to CVB3-infected animals would inhibit myocardial CVB3 infection and improve cardiac function relative to CVB3-infected animals treated with a vector control. We used hemodynamic indices as the best measure of cardiac function and histological measurements to monitor cardiomyopathy after CVB3 infection.
Methods

Coxsackievirus B3
In vitro and in vivo experiments used the genetically characterized, cardiovirulent Nancy strain of CVB3. 17 Methods detailing virus propagation and titration of CVB3 in HeLa cells, as well as storage at Ϫ80°C, before infection of cells or animals have been published previously. 13
Development of AdVs
sCAR-Fc was generated by fusion of the extracellular domain of human CAR with the carboxy terminus of the human IgG1 Fc coding region and inserted into an adenoviral shuttle plasmid that contained improved elements of the Tet-On gene expression system in different configurations. AdVs were generated as described previously. 18 Details of cloning strategies and adenoviral generation are provided in the online-only Data Supplement.
Cell Cultures, Northern Blot, Western Blot, Virus Plaque Assays, and IgG ELISA
HeLa (human cervical carcinoma) cells and HEK293 (human embryonic kidney) cells were cultured in Dulbecco's modified Eagle's medium (Gibco BRL, Karlsruhe, Germany) supplemented with 10% FCS and 1% penicillin/streptomycin. Northern and Western blot analysis and virus plaque assays were performed as described previously. 18 Human IgG ELISA (Bethyl Laboratories Inc, Montgomery, Tex) for detection of the Fc tail of sCAR-Fc was performed according to the supplier's instructions. Details are provided in the online-only Data Supplement.
Murine CVB3 Myocarditis
AdG12 was injected into the jugular vein of 6-to 8-week-old BALB/c mice. Two days after AdV injection, mice were infected with 5ϫ10 4 plaque-forming units (pfu) of CVB3 intraperitoneally. Doxycycline (200 g/mL) was administered orally to the mice via drinking water 2 days before CVB3 infection (prophylactic approach) or concomitantly with or 1 day after CVB3 infection (therapeutic approach). The water was replaced daily by fresh water that contained doxycycline. Seven days after CVB3 infection, the hemodynamic parameters of the mice were analyzed as described previously, 19 then blood was taken and organs were harvested for histopathological analysis. CVB3 positive-strand genomic RNA in tissues was detected by in situ hybridization with single-stranded 35 S-labeled RNA probes as described previously 20 or standard plaque assay for CVB3 as described previously. 19 All animals investigated in the present study were inbred male mice with identical genomes. For this reason, no special randomization algorithm was used. The investigation was performed in accordance with the principles of laboratory animal care and the German law on animal protection.
Statistical Analysis
Statistical analysis of the in vivo measurements was performed with SAS version 9.1 (SAS Institute Inc, Cary, NC). Nonnormally distributed parameters (left ventricular pressure [LVP], dP/dt max , dP/dt min , and virus load in the heart) are described as mean, SD, median, and 25th and 75th percentiles. Prespecified 2-group comparisons [sham (ϪDox) versus sham (ϩDox), AdG12 (ϪDox) versus AdG12 (ϩDox)] of the medians of nonnormally distributed data were performed by Mann-Whitney U test. The option "exact" for small sample sizes was selected (procedure: npar1way). Fisher's exact test was used for analysis of differences between myocarditis scores. Differences were considered significant at PϽ0.05.
Results
Doxycycline-Dependent Regulation of sCAR-Fc Therapy
To achieve doxycycline-dependent sCAR-Fc expression, 2 AdVs were constructed. Each AdV contained 2 expression cassettes, 1 for constitutive expression of the second-generation reverse tetracycline transactivator rtTA-M2, 21 the other for expression of sCAR-Fc from the improved second-generation tetracycline response promoter tight1. 22 The expression cassettes were inserted either in tandem orientation (AdR4) or in opposite orientations (AdG12) into the E1 region of an E1-deleted, E3-deleted adenovirus 5 backbone ( Figures 1A and 1B ). To analyze doxycycline-dependent regulation of AdV-mediated sCAR-Fc expression, HeLa cells were transduced with AdR4 or AdG12 and cultured in the presence or absence of doxycycline. Northern blot analysis found sCAR-Fc mRNA expression to be strictly doxycycline dependent, whereas rtTA-M2 expression was constitutively high (Figure 2A ). However, as detected by phosphorimaging of Northern blots (Figure 2A ), doxycyclineinduced sCAR-Fc mRNA expression was up to 6-fold higher in AdG12-than in AdR4-transduced cells. Therefore, AdG12 was selected for further in vitro and in vivo studies. sCAR-Fc protein was only detectable in AdG12-transduced cells and in the cell culture supernatant in the presence of doxycycline ( Figure 2B , left). As expected, Western blot analysis (under nonreducing conditions) confirmed that sCAR-Fc was expressed as a dimeric protein ( Figure 2B 
Inhibition of CVB3 Infection by AdG12 In Vitro
Next, we studied sCAR-Fc-mediated inhibition of CVB3 in vitro as a function of AdG12 dose, doxycycline concentration, and the dose of CVB3. Transduction of HeLa cells with 5 multiplicities of infection (MOI) of AdG12 and induction with doxycycline 500 ng/mL for 48 hours were sufficient to prevent CVB3 infection in sCAR-Fc-expressing cells completely. Under these transducing conditions, sCAR-Fc expression levels reached a maximum with 29.4 g/mL in the cell culture supernatant. sCAR-Fc expressed from AdG12 efficiently blocked CVB3 doses of up to 2.5 MOI (Figures IIA through IID in the online-only Data Supplement). Therefore, sCAR-Fc expressed by AdG12-transduced cells efficiently inhibited CVB3 infection of these cells, and secreted sCAR-Fc levels were directly related to initial AdG12 MOI and doxycycline concentration.
To assess the potential of AdG12 to suppress ongoing infections, which represents the typical situation encountered in the clinical setting, HeLa cells were transduced with AdG12, and sCAR-Fc expression was induced with doxycycline at different times relative to CVB3 infection. Expression of sCAR-Fc 48 and 24 hours before CVB3 infection resulted in complete inhibition of CVB3 infection in the transduced cells. The inhibitory efficiency of sCAR-Fc was gradually reduced the later the sCAR-Fc expression was induced. However, even if sCAR-Fc expression was induced 24 hours after infection, CVB3 progeny virus number was still reduced approximately 10 6 -fold compared with controls without sCAR-Fc (Figure 3 ), which demonstrates the high efficacy of sCAR-Fc in ongoing CVB3 infections.
Preinfection sCAR-Fc Gene Therapy Prevents Cardiac Dysfunction and Inflammation
Encouraged by the in vitro data, we tested the ability of AdG12-transduced mice to inhibit CVB3-mediated myocar- Figure 1 . Structure of sCAR-Fc-expressing AdVs and mechanism of sCAR-Fc-mediated CVB3 inhibition. A, Schematic of doxycycline-regulated sCAR-Fc-expressing AdVs AdG12 and AdR4. Two expression cassettes, 1 for expression of the doxycycline-dependent transactivator rtTA-M2 and the other for doxycycline-inducible expression of sCAR-Fc, were inserted into the E1 region between nucleotide positions 453 and 3333 of an E1-deleted, E3-deleted adenovirus 5 backbone. AdR4 contains the 2 expression cassettes in a tandem direction, whereas in AdG12, the cassettes were inserted in opposite orientations. B, Mechanism of doxycyclinedependent adenoviral expression of sCAR-Fc and sCAR-Fc-mediated inhibition of CVB3 infection. In the absence of doxycycline, rtTA-M2 is unable to transactivate the tight1 promoter; therefore, sCAR-Fc is not expressed, and CVB3 infection cannot be inhibited (top). In the presence of doxycycline, rtTA-M2 transactivates the tight1 promoter, and sCAR-Fc is expressed and neutralizes CVB3 (bottom). CMV IE p indicates immediate-early CMV promoter; rtTA, reverse tetracycline-controlled transactivator rtTA-M2; tight1, doxycyclinedependent response promoter; sCAR-Fc, fusion protein of the soluble extracellular domain of human CAR and the human IgG1 Fc region; SV40 pA and bGH pA, polyadenylation signal of SV40 and bovine growth hormone; 5ЈITR, nucleotide positions 1 to 453 of adenovirus type 5 containing the left inverted terminal repeat of adenovirus 5 and the packaging signal ⌿; and 3ЈITR, right inverted terminal repeat of adenovirus 5.
ditis. Mice were transduced with AdG12, and sCAR-Fc expression was induced and maintained via constant oral doxycycline administration. The AdG12 dose was reduced to 1ϫ10 10 virus particles per mouse because initial experiments with 3ϫ10 10 particles of AdG12 ( Figure IIIA in the onlineonly Data Supplement) resulted in sCAR-Fc serum levels that easily exceeded therapeutic levels, previously identified to be Ͻ100 ng/mL. 11 Two days after vector transduction, animals were infected with 5ϫ10 4 pfu of CVB3 ( Figure 4A ). At the point of CVB3 infection, circulating sCAR-Fc concentrations were 228.5Ϯ174 ng/mL, and 7 days later, when mice were euthanized, sCAR-Fc concentrations were 99.63Ϯ22.7 ng/ mL. No sCAR-Fc was measured in the AdG12-transduced mice that did not receive doxycycline, which were identical to animals that did not receive AdG12. CVB3-infected mice that did not receive AdG12 or were transduced with AdG12 in the absence of doxycycline administration showed a continuous loss in body weight, which resulted in an average 30% decrease by day 7 after infection. By comparison, CVB3infected mice that received AdG12 and doxycycline only lost roughly 5% of their body weight ( Figure IVA in the onlineonly Data Supplement). Hemodynamics were measured by tip catheter on day 7 after CVB3 infection. AdG12 (ϩDox)treated CVB3-infected mice had significantly improved cardiac contractility and diastolic relaxation compared with CVB3infected animals transduced with AdG12 in the absence of doxycycline (LVP 59Ϯ3.8 versus 45.4Ϯ2.7 mm Hg, median 59 versus 45.8 mm Hg, PϽ0.01; dP/dt max 3645.1Ϯ443.6 versus 2057.9Ϯ490.2 mm Hg/s, median 3526.6 versus 2072 mm Hg/s, PϽ0.01; dP/dt min Ϫ2125.5Ϯ330.5 versus Ϫ1310.2Ϯ330.3 mm Hg/ s, median Ϫ2083.7 versus Ϫ1295.9 mm Hg/s, PϽ0.01). Importantly, hemodynamics of CVB3-infected animals treated with AdG12 (ϩDox) were similar to noninfected control animals ( Figure 4B ). For statistical details, see Tables IA and IB in the online-only Data Supplement. Myocardial histological grading revealed extensive areas of damage, with myocyte necrosis and infiltration of mononuclear cells in CVB-infected control mice and in CVB3-infected AdG12 (ϪDox) mice (myocarditis score of 3 to 4 in both groups). Cell damage and inflammation were completely absent in the AdG12 (ϩDox) group (myocarditis scoreϭ0) and showed histology comparable to that of hearts of noninfected control mice ( Figure 4C ).
Preinfection sCAR-Fc Gene Therapy Inhibits CVB3-Mediated Cardiomyopathy and Pancreatitis
To document whether the absence of pathological changes of the heart correlated with cardiac CVB3 infection, we performed radioactive in situ hybridization experiments to visualize the presence of positive-strand CVB3 RNA at the cellular level with a high sensitivity. Animals in the AdG12 (ϩDox) CVB3-infected group did not show any CVB3infected cells in the heart and no ( Figure 4D ) or minimal (results not shown) levels of CVB3 RNA in the pancreas, HeLa cells were transduced with AdG12 at an MOI of 5. Fortyeight hours later, cell culture supernatant was harvested, preincubated with CVB3 (MOI 0.01 to 0.00001) for 30 minutes at 4°C, deposited to the AdG12-transduced cells for 30 minutes, and then replaced with fresh medium. CVB3 replication was analyzed by plaque assays after 48 hours of culture. For induction of sCAR-Fc expression, doxycycline (Dox; 1 g/mL) was added to the medium at the time points indicated, from 48 hours before to 24 hours after CVB3 infection.
which is the primary site of CVB replication and the most susceptible organ for CVB infection in mice. In contrast, CVB3-infected and AdG12 (ϪDox) CVB3-infected mice showed high prevalence of CVB3 RNA in the heart and pancreas. In other organs (spleen, liver, kidney, intestine, and lung), CVB3 RNA was undetectable in AdG12 (ϩDox) and in the control groups by in situ hybridization ( Figure 4D ). Thus, sCAR-Fc efficiently protected mice from virus entry and subsequent replication in the heart and other organs.
Therapeutic sCAR-Fc Gene Therapy Improves Cardiac Contractility and Reduces Cardiomyopathy
We next analyzed the efficacy of sCAR-Fc gene therapy in a therapeutic approach. Mice were transduced with AdG12, and doxycycline-mediated induction of sCAR-Fc was delayed either to be concomitant with CVB3 infection (2 days after transduction) or to occur 1 day after CVB3 infection (day 3 after transduction; Figure 5A ). By use of this experimental approach, low levels of sCAR-Fc (28.4 ng/mL) were just detectable at 16 hours after induction (ie, either 16 hours or 40 hours after CVB infection for the 2 groups, respectively; Figure IIIB in the online-only Data Supplement). Body weights for the concomitant-induction group were reduced by an average of 4%, whereas body weights for the 1-day delayed-induction group decreased by an average of 14% and that of untreated CVB3-infected controls decreased by an average of 18% by day 7 after infection ( Figure IVB in , with values that surprisingly were in the range of uninfected control animals. The diastolic relaxation in the CVB3-infected group with concomitant sCAR-Fc expression showed no significant improvement relative to control vectortransduced animals but revealed a clear trend toward improvement (dP/dt min Ϫ3756.6Ϯ1418 versus Ϫ2212Ϯ745.7 mm Hg/s, median Ϫ3624.3 versus Ϫ2217.43 mm Hg/s, Pϭ0.073). However, animals with induced sCAR-Fc expression 1 day after CVB3 infection did not show improved hemodynamics ( Figure 5B ). For statistical details, see Tables IIA and IIB in the online-only Figure 5C ) and significantly decreased infectious CVB3 titers in the heart compared with CVB3-infected control animals ( Figure 5D ). For statistical details, see Tables IIC and IID in the online-only Data Supplement. However, all animals in these groups with sCAR-Fc expression after CVB3 infection showed high pathological scoring and inflammatory damage to the pancreas (pancreatitis score 3 to 4; not shown), which indicates that only prophylaxis was capable of saving the pancreas from destruction.
Discussion
In the present study, we report inhibition of CVB3 infection by a sCAR-Fc fusion protein expressed from the newly developed doxycycline-regulated adenovector AdG12. sCAR-Fc expressed from AdG12 inhibited CVB3 infection of susceptible target cells in vitro and inhibited CVB3 Figure 5 . AdG12-mediated therapeutic sCAR-Fc expression in murine CVB3 myocarditis. A, Application scheme and timeline of sample preparation. Twelve mice were transduced with 1ϫ10 10 particles of AdG12 and infected with CVB3 2 days later. sCAR-Fc expression was induced through doxycycline (Dox) in 5 animals concomitantly with (AdG12 ϩDox, 0d) and in 7 animals 1 day after (AdG12 ϩDox, 1d) CVB3 infection, respectively. Seven mice were transduced with 1ϫ10 10 particles of the control AdV (AdG12 trunc ϪDox), which has overall sequence identity to AdG12 but does not express sCAR-Fc, and infected with CVB3 2 days after transduction. Eleven mice were sham operated, and 4 of them were treated with doxycycline and infected with CVB3 (sham ϩDox). infection of the myocardium in vivo. As a consequence, sCAR-Fc prevented heart injury and cardiac inflammation and prevented the development of systolic and diastolic cardiac dysfunction in CVB3-infected animals.
Previous reports demonstrated inhibition of CVB3 myocarditis through application of purified recombinant sCAR-Fc 13 or through delivery of sCAR-Fc from plasmids. 11 However, plasmid-based transgene expression in vivo is inefficient owing to low-level and transient protein expression, which severely limits its use in acute CVB3 infections with high virus load. 11 Furthermore, methods that are used to enhance plasmid uptake, eg, electroporation, appear to be inapplicable for therapeutic use in humans. Generation of purified recombinant proteins is time consuming and expensive, and ex vivo production of the proteins in bacterial or mammalian cells runs the risk of copurifying proinflammatory substances (ie, lipopolysaccharide) or altering the glycosylation of proteins that accelerate their systemic clearance. Moreover, repeated readministration frequently is necessary to maintain therapeutic protein levels for both the plasmidbased and the recombinant protein approach.
Therefore, we focused on the development of a gene therapy approach that used an AdV as a carrier to deliver sCAR-Fc. This viral vector type enables fast, strong, persistent expression of therapeutic genes in vivo. Intravenous AdG12 application resulted in a typical expression profile of sCAR-Fc after its doxycycline-mediated induction with the highest sCAR-Fc serum levels at days 4 and 5 after induction. Most importantly, sCAR-Fc was already detectable in the serum 16 hours after induction with doxycycline, and serum levels rapidly increased to Ͼ100 ng/mL within 1 day after transduction. These levels exceeded serum sCAR-Fc levels measured after plasmid-based gene transfer, and moreover, they exceeded the sCAR-Fc serum concentration that has been shown to be required to protect animals from CVB3induced myocarditis. 11 In addition, if the AdG12 dose of 1ϫ10 10 particles used for mice is adapted to human weight, it would be within the range of AdV doses previously used in clinical trials, which suggests that therapeutically relevant sCAR-Fc serum levels could be produced in humans after AdG12 treatment.
CVB3 infection is known to evoke severe left ventricular systolic and diastolic failure in humans during acute infection 23 and in the present well-established experimental model. 24 Here, we confirm cardiac dysfunction in CVB3-infected mice as reduced left ventricular contractility and relaxation.
The present study demonstrates for the first time that CVB3-induced cardiac failure can be prevented by sCAR-Fc, because the hemodynamic parameters (LVP, dP/dt max , and dP/dt min ) of sCAR-Fc-expressing AdG12 (ϩDox)-treated mice were significantly better than those of untreated CVB3infected mice, almost reaching the values measured in uninfected control animals. The effect was visible when sCAR-Fc was expressed prophylactically, but much more importantly, LVP and dP/dt max were also improved if sCAR-Fc was induced concomitantly with CVB3 infection, which demonstrates a strong potential for therapeutic efficacy of the sCAR-Fc gene therapy approach after CVB3 infection. Although sCAR-Fc induction corresponding to approximately 40 hours after CVB3 infection did not improve heart function or pancreatitis, histological cardiomyopathy grading and myocardial virus load were decreased significantly, which likely would lessen the risk of development of dilated cardiomyopathy. In agreement with previous reports, 11, 25 prophylactic sCAR-Fc delivery abrogated pancreatic and cardiac inflammation and necrosis and resulted in negligible virus load as assessed by in situ visualization of CVB3 genome presence and parenchymal virus titer. The present study improves on previous methods of delivering sCAR-Fc by showing higher and more prolonged circulating levels of decoy receptor, without the variability of plasmid delivery or expense and potential copurification of contaminants associated with the production of purified recombinant proteins.
The decreased efficacy of sCAR-Fc gene therapy when administered after CVB3 infection likely reflects the inability of sCAR-Fc to penetrate sufficiently into the parenchyma of the heart and pancreas once initial virus infection has been established and the virus predominantly spreads between adjacent cells or perhaps is unable to fully neutralize the initially high levels of CVB3 in the serum that are seen early in infection. 26 The present results were similar to those previously reported that examined administration of purified recombinant sCAR-Fc 13 to CVB3-infected mice, but the present results advance these studies by showing a significant decrease in cardiac inflammation, virus load, and cardiac function if treatment begins within the first 24 hours of CVB infection.
The present in vitro data demonstrate that sCAR-Fc could neutralize up to 10 4 CVB3 particles (results not shown) and reduce CVB3 replication by up to 11 orders of magnitude. In addition to virus-neutralization capacity, we cannot rule out other antiinflammatory effects of sCAR-Fc. Other decoy receptor Fc fusion proteins (eg, CD55-Fc) and purified pooled immunoglobulins have been shown to decrease myocardial lesion area, inflammation, viral replication, and viral progeny synthesis in CVB3 infection in vivo; however, these were not as effective as sCAR-Fc. 13, 25, 27 CAR has also been reported to bind human IgG and IgM, which suggests a further role for CAR in immune system interactions. 28 Future studies examining the ability of sCAR-Fc to modulate cardiomyopathy in mouse models by other nonenteroviral pathogens will be needed to address this possibility.
Extension of the efficacy of sCAR-Fc beyond 24 hours after CVB infection may be achieved by combining viral neutralization with potent antiinflammatory therapies (for example, targeting proinflammatory cytokines, which have also been shown to be potent in inhibiting CVB3-induced myocarditis 29, 30 ). Another potential approach would be to combine sCAR-Fc with RNA interference that specifically targets intracellular CVB3 during replication. In this context, we have shown that small hairpin RNAs directed against CVB3 RNA-dependent RNA polymerase were capable of increasing systolic and diastolic function in CVB3-infected animals. 19 The safety of viral vectors plays an important role in gene therapy applications. AdG12 treatment did not induce side effects in CVB3-infected or uninfected animals. Furthermore, because AdG12 is a first-generation AdV, its presence in the body is self-limited to several weeks. 31 Moreover, the doxycycline-dependent control of sCAR-Fc expression in AdG12 enables on/off switching and confers the ability to shut off transgene expression at any point after delivery, thereby further increasing its safety. It is a hallmark of AdG12 that there is no leaky sCAR-Fc expression in the absence of the inducer drug, doxycycline. This was achieved through the use of improved key components of the Tet-On gene expression system, the second-generation transactivator (rtTA-M2) and a new response promoter (tight1). Each was shown to be able to reduce background activity of the Tet-On system, 21, 22 but in contrast to the results presented here, the use of rtTA-M2 with the original tetracycline-response promoter, TRE, still resulted in leaky expression of the Tet-On system in the context of AdVs. 32, 33 The resistance of tight1 to nonspecific transactivation may be responsible for the lack of leakiness of AdG12. Moreover, the use of improved components of the Tet-On system enables side-by-side insertion of cytomegalovirus-promoter-driven rtTA-M2 and tight1-promoter-driven sCAR-Fc expression cassettes into the adenoviral E1 region, thereby simplifying the construction of doxycycline-regulated AdVs.
Host immune responses often prevent readministration of an AdV of the same serotype. 34 This may limit the potential clinical utility of our proof-of-concept approach in cases in which repeated AdV administration would be necessary, eg, to extend the treatment period. However, administration of AdVs derived from different serotypes, 35 or the use of significantly less immunogenic vectors that are derived from adeno-associated virus, is an available tactic to overcome this limitation.
In conclusion, here we show therapeutic efficacy in treating CVB3 myocarditis with sCAR-Fc delivered from a pharmacologically regulated AdV. The treatment was highly efficient, without clinically observable side effects, and led to improved hemodynamics and heart function in CVB3infected animals. For the purpose of the present study, the chosen sample sizes were appropriate to document statistical significance; however, if the prognostic relevance of this treatment, including survival changes, is to be investigated in the future, considerably larger study groups must be used. The combination of the sCAR-Fc approach with gene therapy methods represents a promising new approach for treatment of cardiac CVB3 infections.
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